Article
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Molecular cancer therapeutics - 1 Feb 2011
Sunaga Noriaki, Shames David S, Girard Luc, Peyton Michael, Larsen Jill E, Imai Hisao, Soh Junichi, Sato Mitsuo, Yanagitani Noriko, Kaira Kyoichi, Xie Yang, Gazdar Adi F, Mori Masatomo, Minna John D
Abstract excerpt
Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non-small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-mutant NSCLC cells, but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.